Johnson & Johnson Corporate Analysis
The purpose of this paper is to introduce the reader to the Johnson and Johnson Corporation and its financial status. First, this paper will surmise a brief history of the company and its products. Second, this paper will explain Johnson and Johnson's operational conditions. It will explore what the company does and who the direct competition is at this time. The paragraphs below will examine these conditions and expectations of these conditions for the future. Third, this paper will explore current methods to assess the company's financial condition. These methods will include looking at Johnson and Johnson's annual report to conclude different financial indicators. The tools used will be ratio analysis and leverage analysis with a brief explanation of how these tools work. Fourth, there will be an evaluation of Johnson and Johnson. What have they done to maximize their potential? What are they planning on doing in the future to remain solid? Is their stock worth purchasing at this time? Lastly, there will be a recommendation for Johnson and Johnson. This recommendation will act as a strategic plan outlining ways to maximize their potential.
History
The development of the first ready-made, ready-to-use surgical dressings by Johnson and Johnson in the mid-1880s marked not only the birth of a company, but also the first practical application of the theory of antiseptic wound treatment. Up until then many doctors did not give air-born germs much thought (Johnson and Johnson, par. 1). It was the innovative thinking of Robert Wood Johnson and his brothers that made the company what it is today. (Johnson and Johnson, par. 7). Today the corporation of Johnson and Johnson compromises a family of over 200 companies worldwide marketing healthcare products worldwide in 175 countries. For the sake of this paper, it will look the corporation's domestic success and only touch on international activities.
Products
The company produces a wide range of products for the healthcare field. These products range from baby care, first aid and hospital products to prescription pharmaceuticals, diagnostics and products relating to family planning, dermatology and feminine hygiene. Recently, Johnson and Johnson entered other innovative fields of biotechnology and robotics. Many of these new products aid in bettering the lives of paralysis, fire and cancer victims. Their strong brand identity makes their products easily recognizable and this translates into sales.
Operational Conditions
What do they do?
What Johnson and Johnson does is continue to grow in a field that can be very competitive due to new technologies and medical breakthroughs. This requires expensive research and development but also the creative spirit to think outside the box. They have managed to differentiate themselves from their competition by diversifying their product line and portfolio by partnering and in some cases buying out other companies with these products. They have been able to do this only because of their international status and brand identity. Still at this time because of the United States economy, market competition, the rising costs of research and technology, Johnson and Johnson remains strong as a corporation to work for and invest in. According to Yahoo Finance, because of average financial numbers, where their future lie remains unseen.
The Marketplace
Johnson and Johnson does business within the healthcare sector and has industry membership in the major drug field. Because of the nature of this industry and the risk involved with drug manufacture, it can be very difficult to gage and predict its performance over time. Right now the drug industry is suffering the fallout from the recall of Celebrex. There are also other warnings being recently about other drugs such as Strattera. There has been much media scrutiny of the FDA and its prior approval of drugs like Accutane. What does this mean for the market and its companies? For the future, it may mean increased drug testing, which can be extremely costly, and time consuming. This may also mean looking to other markets such as Europe and Asia where the laws are different to take up the slack on the American market.
The Competition
Johnson and Johnson's direct competition in the drug field is GlaxoSmithKline, Pfizer, Novartis AG and Abbott Laboratories to name a few. Part of the interesting element of the drug industry is...
Johnson and Johnson Annual Report Review Financial Report Review Company: Johnson and Johnson Consolidated Balance Sheets Total Assets: $121,347,000,000 Total Liabilities: $56,521,000,000 Total Shareholder's Equity: $64,826,000,000 Company's Retained Earnings: 85,992,000,000 Shares of common stock the company has been authorized to issue: 4,320,000,000 shares Shares the company has issued: 3,119,843,000 shares Cash (cash and cash equivalents): $14,911,000,000 Decrease in cash and cash equivalents during 2012: $9,631,000,000 F: Increase in cash and cash equivalents during 2011: $5,187,000 Consolidated Statement of Earnings Essentially, the term "consolidated" as used
Corporate Governance Two different, yet related corporate governance definitions have been presented in this paper (Mallin, 2006: 3). Sometimes they cause confusions and controversy and ultimately affect the implementation of tightening of governance (Windsor, 2009). The 1992 Cadbury Report, which presented the major proposals for tightening governance, described governance as the system through which firms are managed, regulated and supervised (Cadbury, 1992: 15). The fundamental agency idea emphasizes that corporate governance has
Johnson Bank v. George Korbaken Company Johnson Bank v. George Korbakes Company Over the last several years, the role of the auditor has been continually evolving. This is because financial institutions are relying on the information they are provided with to help them make better choices in the long-term. However, there are times when these firms may not have accurate figures and erroneously report their findings. When this happens, there is a
Figure 1: Analysis of the Johnson & Johnson Value Chain Sources: (Atherton, Kleiner, 1998) (Johnson & Johnson Investor Relations, 2012) Variability in capacity planning and constraint-based modeling of demand has also led Johnson & Johnson to adopt and standardize on Lean Six Sigma as part of its quality management and constraint-based planning strategies (Hunter, Schmitt, 1999). Based on an analysis of their annual reports and filings with the Securities and Exchange (SEC)
As with many pharmaceutical products manufacturers, the extent of supply chain and quality performance has a direct effect on distribution, profitability and services performance as well (Stevenson, 2012). Beginning with supply chain management, J&J has an intensively level of supplier audits they expect each supplier to pass and also randomly be able to manage as they provide materials, components and subassemblies to the company (Wechsler, 2011). Supplier audits form the
Additionally, it has been observed that whenever companies implement strategies of CSR, they do this not out of individual choice and desire, but as a result of imposed legislations. "All of these decisions are made under the mandatory legal rules embodied in employment and labor law, workplace safety law, environmental law, consumer protection law, and pension law. Such rules, because they often apply to all businesses, are not susceptible to
Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.
Get Started Now